Literature DB >> 7686690

FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

A W Thomson1, P B Carroll, J McCauley, J Woo, K Abu-Elmagd, T E Starzl, D H Van Thiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7686690      PMCID： PMC2966151          DOI： 10.1007/bf00192307

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  50 in total

1.  Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.

Authors: 
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

Review 2.  Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis.

Authors:  G S Firestein
Journal:  Curr Opin Rheumatol       Date:  1992-06       Impact factor: 5.006

Review 3.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat.

Authors:  L Castaño; G S Eisenbarth
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

6.  Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.

Authors:  K Tamura; J Woo; N Murase; G Carrieri; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 7.  The forces driving autoimmune disease.

Authors:  I M Roitt; P R Hutchings; K I Dawe; N Sumar; K B Bodman; A Cooke
Journal:  J Autoimmun       Date:  1992-04       Impact factor: 7.094

8.  The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.

Authors:  Y Hiraoka; C Kishimoto; M Kurokawa; H Ochiai; S Sasayama
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

9.  Soluble IL-2 receptor in patients with primary nephrotic syndrome.

Authors:  I Ohno; H Gomi; H Matsuda; H Nakano; H Matsumoto; K Kodama; T Shibasaki; F Ishimoto; O Sakai
Journal:  Nihon Jinzo Gakkai Shi       Date:  1991-05

10.  Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats.

Authors:  H Kawashima; Y Fujino; M Mochizuki
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-08       Impact factor: 4.799
View more
  9 in total

1.  Tacrolimus in refractory polymyositis with interstitial lung disease.

Authors:  C V Oddis; F C Sciurba; K A Elmagd; T E Starzl
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

2.  Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.

Authors:  Akiko Yamada; Yusei Ohshima; Nemuko Omata; Motoko Yasutomi; Mitsufumi Mayumi
Journal:  Eur J Pediatr       Date:  2004-07-08       Impact factor: 3.183

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Diabetes tolerogenic vaccines targeting antigen-specific inflammation.

Authors:  Shuang Geng; Huiyuan Zhang; Xian Zhou; Yue He; Xiaoqian Zhang; Xiaoping Xie; Chaofan Li; Zhonghuai He; Qingling Yu; Yiwei Zhong; Douglas B Lowrie; Guoxing Zheng; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 6.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

Review 7.  Therapeutic advances in immunosuppression.

Authors:  A W Thomson; J V Forrester
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

8.  Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.

Authors:  B Lemster; L L Huang; W Irish; J Woo; P B Carroll; K Abu-Elmagd; H R Rilo; N Johnson; R Russell-Hall; J J Fung
Journal:  Autoimmunity       Date:  1994       Impact factor: 2.815

9.  Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes.

Authors:  A W Thomson; S Satoh; A K Nüssler; K Tamura; J Woo; J Gavaler; D H van Thiel
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.